Anavex Life Sciences Corp. (NASDAQ:AVXL)’s share price was up 3.6% during mid-day trading on Monday . The stock traded as high as $2.60 and last traded at $2.60, with a volume of 376,590 shares changing hands. The stock had previously closed at $2.51.

Several equities analysts have recently issued reports on AVXL shares. Zacks Investment Research upgraded Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research report on Tuesday, May 31st. Maxim Group reiterated a “buy” rating on shares of Anavex Life Sciences Corp. in a research report on Monday, June 6th. Finally, FBR & Co reiterated a “buy” rating on shares of Anavex Life Sciences Corp. in a research report on Wednesday, June 22nd.

The company’s market cap is $92.85 million. The stock has a 50-day moving average price of $3.10 and a 200 day moving average price of $4.64.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last released its quarterly earnings data on Thursday, August 11th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.03. On average, equities analysts anticipate that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in AVXL. Squarepoint Ops LLC bought a new stake in Anavex Life Sciences Corp. during the first quarter valued at $107,000. American International Group Inc. acquired a new position in shares of Anavex Life Sciences Corp. during the second quarter valued at approximately $115,000. Nationwide Fund Advisors acquired a new position in shares of Anavex Life Sciences Corp. during the second quarter valued at approximately $130,000. Rhumbline Advisers acquired a new position in shares of Anavex Life Sciences Corp. during the second quarter valued at approximately $192,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Anavex Life Sciences Corp. during the first quarter valued at approximately $274,000. Institutional investors own 10.72% of the company’s stock.

Anavex Life Sciences Corp. Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

5 Day Chart for NASDAQ:AVXL

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.